Neurochemistry

DIMERx Secures Global Rights to a Novel Amino Acid Prodrug Dimer Developed at Massachusetts General Hospital

Retrieved on: 
星期三, 五月 22, 2024
Health, Other Health, Research, Pharmaceutical, Science, Biotechnology, MGH, Patient, Massachusetts General Hospital, Dicarboxylic acid, Neurochemistry, The central science, Hospital

DIMERx, Inc. , an advance-stage biopharmaceutical company, announced today that it has secured rights from Massachusetts General Hospital (MGH) for a novel amino acid dimer to be developed for two rare disease indications in the U.S. and as a proprietary medical food for ex-U.S. markets.

Key Points: 
  • DIMERx, Inc. , an advance-stage biopharmaceutical company, announced today that it has secured rights from Massachusetts General Hospital (MGH) for a novel amino acid dimer to be developed for two rare disease indications in the U.S. and as a proprietary medical food for ex-U.S. markets.
  • This exclusive patent license agreement marks a pivotal step in harnessing the therapeutic potential of amino acids as drugs.
  • Through this strategic collaboration, DIMERx aims to challenge treatment paradigms across multiple health conditions.
  • “DIMERx has been on the forefront of harnessing therapeutic potential of compounds with covalent bonds through dimerization.

Ibogaine By David Dardashti Offers New Treatment Procedure In Dedication Of Autism Awareness Month

Retrieved on: 
星期日, 四月 21, 2024
Brain, Diagnosis, Neurochemistry, Autism spectrum, Spectrum, Anxiety, Asperger syndrome, Depression, Emotion, Linux

MIAMI, April 21, 2024 (GLOBE NEWSWIRE) -- To commemorate Autism Awareness Month, Ibogaine By David Dardashti is reintroducing its autogenic self-creation therapy with ibogaine treatment for the autistic community.

Key Points: 
  • MIAMI, April 21, 2024 (GLOBE NEWSWIRE) -- To commemorate Autism Awareness Month, Ibogaine By David Dardashti is reintroducing its autogenic self-creation therapy with ibogaine treatment for the autistic community.
  • At his high school years, Gavriel Dardashti, the founder of Ibogaine By David Dardashti, was diagnosed with Aspergers.
  • He has pioneered the development of the autogenic self-creation therapy that is incorporated with ibogaine treatment for autism.
  • Ibogaine By David Dardashti invites those suffering from autism to seek out its treatment procedure and see how it can benefit their condition.

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

Retrieved on: 
星期二, 三月 5, 2024
Axonal transport, Tauopathy, Neuron, CRVO, Cell biology, DLB, Plasma, Medical laboratory, MB, Phosphorylation, Overalls, FTD, GS, Vrije Universiteit Amsterdam, Publication, MAPK, Glial fibrillary acidic protein, GFAP, Axon, Brain, CNR, IW, EM, SDL, UCL, RAF kinase, Alpha-synuclein, Conference, Biomarker, AG, Lewy body, GBA, MD, Neurochemistry, PDF, JC, CP, Patient, Dementia, Basal forebrain, JA, Medical imaging

BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced the presentation of biomarker data from the AscenD-LB Phase 2a trial of neflamapimod in patients with dementia with Lewy bodies (DLB), demonstrating that neflamapimod reduces plasma levels of glial fibrillary acidic protein (GFAP) compared placebo, and that the effects of neflamapimod on GFAP were inversely correlated to change in CDR-SB (reduction in GFAP associated with improvement in CDR-SB, and increase in GFAP associated with worsening in CDR-SB). These data will be featured in a poster presentation at the 18th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024, being held both virtually and in Lisbon, Portugal from March 5–9, 2024. In addition, academic researchers from UCL will be presenting data in a separate poster at the meeting demonstrating that p38MAPK inhibition, including with neflamapimod specifically, improves tau-induced axonal transport defects both in vitro and in a tauopathy mouse model.

Key Points: 
  • These data will be featured in a poster presentation at the 18th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024, being held both virtually and in Lisbon, Portugal from March 5–9, 2024.
  • “The effects on GFAP, particularly the association between GFAP response and clinical outcomes, further support that neflamapimod is clinically efficacious in patients with DLB,” said John Alam, MD, Chief Executive Officer of CervoMed.
  • A PDF copy of the GFAP poster presentation will be available on the “ Presentations and Publications ” section of the CervoMed website.
  • Title: NEW INSIGHTS IN THE DEVELOPMENT OF BIOMARKERS, IMAGING, AND THERAPY OF ALPHA-SYNUCLEIN, LRKK2, AND GBA PATHOLOGIES

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

Retrieved on: 
星期三, 三月 6, 2024
Senior, Research, SAB, Lecanemab, Clinical Chemistry (journal), Neuroimaging, Lund University, University, Associate, Henrik, Key, School, OGA, Principal, Research and development, Queen Silvia of Sweden, Young, Brain, Therapy, Pharmacology, SAN, UCL, Geriatric psychiatry, Eric, Biomarker, Yale School of Medicine, ACTC, Sahlgrenska University Hospital, University College London, Division, Neurochemistry, FDA, Public health, Phase II, Neurology, Senior advisor, Executive Committee, Patient, Cognition, Yale school, European Grand Prix, Biogen, Pharmaceutical industry

LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).

Key Points: 
  • LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).
  • Asceneuron is advancing development of its lead asset ASN51 into Phase II clinical development targeting Alzheimer's disease.
  • The Scientific Advisory Board members have vast experience in clinical trial design and biomarkers and will help support this promising program through Phase II clinical development.
  • I am honored to have these stellar neurodegenerative experts join our SAB at a fundamental time of development.

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

Retrieved on: 
星期三, 三月 6, 2024
Senior, Research, SAB, Lecanemab, Clinical Chemistry (journal), Neuroimaging, Lund University, University, Associate, Henrik, Key, School, OGA, Principal, Research and development, Queen Silvia of Sweden, Young, Brain, Therapy, Pharmacology, SAN, UCL, Geriatric psychiatry, Eric, Biomarker, Yale School of Medicine, ACTC, Sahlgrenska University Hospital, University College London, Division, Neurochemistry, FDA, Public health, Phase II, Neurology, Senior advisor, Executive Committee, Patient, Cognition, Yale school, European Grand Prix, Biogen, Pharmaceutical industry

LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).

Key Points: 
  • LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).
  • Asceneuron is advancing development of its lead asset ASN51 into Phase II clinical development targeting Alzheimer's disease.
  • The Scientific Advisory Board members have vast experience in clinical trial design and biomarkers and will help support this promising program through Phase II clinical development.
  • I am honored to have these stellar neurodegenerative experts join our SAB at a fundamental time of development.

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

Retrieved on: 
星期一, 一月 22, 2024
Canada Research Chair, Multiple system atrophy, Patient, Biology, Emeritus, Research, Associate, Dementia, University, Neurochemistry, PMN, Cell biology, American Academy, Epitope, Vaccine, MSA, Anatomy, Physiology, Neurodegenerative disease, Microbiology, Vaccination, AAN, Immunology, PROMIS, Neuroscience, Therapy, Synucleinopathy, CAD, VIDO

“We are excited about the potential of our ground-breaking technology in neurodegenerative diseases,” said Neil Warma, Chief Executive Officer of ProMIS Neurosciences.

Key Points: 
  • “We are excited about the potential of our ground-breaking technology in neurodegenerative diseases,” said Neil Warma, Chief Executive Officer of ProMIS Neurosciences.
  • Using a proprietary computational platform, ProMIS identified potential conformational epitopes (misfolded portions) unique to toxic alpha-synuclein involved in synucleinopathies.
  • Formulations of several of these epitopes were tested in mouse vaccination studies leading to the selection of a lead vaccine candidate for testing in mouse models replicating cognitive and motor deficits of human disease.
  • Results from the vaccination studies are being submitted for presentation at the 2024 meeting of the American Academy of Neurology (AAN) taking place from April 13-18, 2024 in Denver, Colorado.

Brain Mechanism Teaches Mice to Avoid Bullies

Retrieved on: 
星期三, 一月 24, 2024
Dai, Psychiatry, Social isolation, Hypothalamus, Neurochemistry, Oxytocin, Research, Animal, Sleep, Parenting, Social skills, Face, Hunger, Hormone, Social anxiety, Mouse, Freezing, Behavior, Physiology, Social, Disorder, Cell, NYU, Human, Pain, NYU Langone Health, Nature, Doctor of Philosophy, Spectrum, National Institutes of Health, Social defeat, Smell, Bangladesh Technical Education Board, Brain

NEW YORK, Jan. 24, 2024 /PRNewswire/ -- Like humans, mice live in complex social groups, fight over territory and mates, and learn when it is safer to avoid certain opponents. After losing even a brief fight, the defeated animals will flee from the mice that hurt them for weeks afterward, a new study shows.

Key Points: 
  • After losing even a brief fight, the defeated animals will flee from the mice that hurt them for weeks afterward, a new study shows.
  • The team had previously found that this special region, called the anterior ventrolateral part of the ventromedial hypothalamus (aVMHvl), helps rodents defend themselves against bullies' attacks.
  • The study showed that when rival mice first meet, scent information about opponents is not strong enough to activate aVMHvl cells to prompt a retreat.
  • In addition, the findings revealed that pain prompted the immediate activation of oxytocin-releasing brain cells located right next to the aVMHvl.

BrainSpec Receives Full FDA Clearance to Begin Using AI-Backed Solution for Non-Invasive Brain Chemistry Measurement

Retrieved on: 
星期一, 十一月 27, 2023
Traumatic brain injury, Glioma, Classification, Television, Brain, Isocitrate dehydrogenase, Hope, Alzheimer's disease, Neurochemistry, Dana–Farber Cancer Institute, Tissue, Hospital, Disease, Database, MRS, Patient, Neuroradiology, FDA, Neoplasm, Neuro-Oncology (journal), IDH, Epilepsy, Multiple sclerosis, Diagnosis, Software, Doctor of Philosophy, MRI, Physician, Health, Cone Health Women's Hospital, Medical imaging, MD, Brigham

BOSTON, Nov. 27, 2023 /PRNewswire/ -- BrainSpec, the comprehensive software platform enabling virtual biopsies of the brain, has been awarded clearance by the FDA to begin using their Magnetic Resonance Spectroscopy (MRS) platform to provide non-invasive measurement of brain chemistry to support the diagnostic process in the most common brain-related illnesses, including Alzheimer's disease, multiple sclerosis, epilepsy, brain tumors, and more. This marks the first-time software using a reference database of brain chemistry has been included in an FDA clearance.

Key Points: 
  • First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease and Traumatic Brain Injury.
  • BrainSpec Core™ shows 85% sensitivity and 90% specificity in detecting 2-Hydroxyglutarate, an oncometabolite present in low-grade gliomas.
  • This marks the first-time software using a reference database of brain chemistry has been included in an FDA clearance.
  • By using non-invasive imaging, BrainSpec Core™ measures concentrations of chemicals in the brain in order to create a virtual biopsy using standard MRI scanners.

Thesis Personalizes Customer Experience for Immediate Customer Satisfaction Increase with Medallia

Retrieved on: 
星期三, 十一月 8, 2023
Professional Services, Health, Technology, Human Resources, Software, General Health, Customer experience, Environment, Feedback, Morale, Organization, Neurochemistry, Online shopping, Sales, Thesis, Medallia

Medallia, Inc. , the global leader in customer and employee experience, today announced Thesis , one of the pioneers of cognitive enhancers, has seen an immediate impact after deploying Medallia.

Key Points: 
  • Medallia, Inc. , the global leader in customer and employee experience, today announced Thesis , one of the pioneers of cognitive enhancers, has seen an immediate impact after deploying Medallia.
  • In just the first 30 days with Medallia, Thesis’ survey response rate has increased from 4.4% to 13.3% and its customer satisfaction from 90% to 93.2%.
  • The company selected Medallia Agent Connect to help its contact center agents better understand customers and deliver more individualized service.
  • “Personalizing every experience is at the core of what we do at Medallia, so to see how Thesis has already taken this to the next level has been incredible,” said Simon Gough, VP of Product, Customer Experience, at Medallia.

Dr. Hartmut Tintrup joins Cellbox Solutions GmbH as new CEO

Retrieved on: 
星期三, 十一月 1, 2023
Goethe University Frankfurt, Organization, Exelixis, Doctor of Philosophy, Research, CGT, Neurochemistry, Cell, Hartmut, Patient, Fine chemical

Cologne, Germany — November 1, 2023 - Cellbox Solutions GmbH , a leading provider of live cell logistics solutions for research, development and shipment of cell-based therapies and cellular diagnostics, today announced that Dr. Hartmut Tintrup has joined Cellbox Solutions GmbH as Chief Executive Officer.

Key Points: 
  • Cologne, Germany — November 1, 2023 - Cellbox Solutions GmbH , a leading provider of live cell logistics solutions for research, development and shipment of cell-based therapies and cellular diagnostics, today announced that Dr. Hartmut Tintrup has joined Cellbox Solutions GmbH as Chief Executive Officer.
  • Hartmut joins the Cellbox team from Lonza, where he served as Global Head Business Development in the Cell & Gene Technologies Business Unit.
  • I am excited to work closely together with Hartmut,” commented Prof. Kathrin Adlkofer, PhD, Founder of Cellbox Solutions GmbH.
  • I am convinced that Cellbox´ technologies will enable CGT players on the market to bring more therapies to patients,” commented Dr. Hartmut Tintrup.